Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: FTSE +0.1%, DAX +0.4%, CAC +0.3%, IBEX +0.4%, MIB +0.2%

Jun 30 ,2025

  • Synopsis

    • European equity markets set to open broadly higher, extending last week's gains when the STOXX Europe 600 ended +1.32%.

    • Asian equities mixed Monday. Japan outperforming with Nikkei reaching 12-month high. Hang Seng retreating following China PMI beat. S&P 500 futures advancing further after US indexes capped off strong weekly gain. Crude extending declines ahead of another expected OPEC+ production hike. Bitcoin back to two-week high.

    • In trade developments, Canada to rescind digital services tax after Trump threatened to pull out of trade talks on Friday. Trump said he doesn't think he'll need to extend tariff 9-Jul deadline, contrasting somewhat with Treasury Secretary Bessent. Somewhat better news on US-China trade talks after both sides confirmed details on framework agreement where China relaxes rare earth exports and US removes countermeasures. Elsewhere, Trump teased "very big" trade deal with India with Delhi officials reportedly extending their stay in Washington. US-Japan talks appear stuck over auto tariffs. Taiwan touted 'constructive progress' following recent talks with US.

    • In central banks, ECB Forum on Central Banking (through Wed) with ECB's Lagarde opening speech in the evening. Reportedly the bank wants to present the results of a strategy review during the event.

    • This week's agenda also sees Jun manufacturing/services PMIs and preliminary CPIs from across the region and among the handful of expected earnings/updates are J Sainsbury (SBRY.LN), Kion Group (KGX.GR) and Sodexo (SW.FP). Of note, markets in the USA close early on Thu and are closed on Fri for Independence Day holiday.

    • European macro data releases out today include Germany Jun preliminary CPI, May retail sales, UK Q1 final GDP, May mortgage approvals, M4 money supply, Italy Jun preliminary CPI, Sweden May retail sales, Switzerland Jun leading indicators - KOF, Eurozone May M3 money supply, Denmark Q1 final GDP, May unemployment rate, Greece May PPI, Apr retail sales, Ireland Jun preliminary HICP, May retail sales, Portugal Jun preliminary CPI

    • On the corporate front this morning, 1&1 AG (1U1.GR) guides FY adjusted EBITDA €545M vs prior guidance €571M and FactSet €575.0M. Volkswagen (VOW.GR) is increasing its stake in Rivian (RIVN); now transferring second tranche of $1B, according to dpa. Duerr (DUE.GR) sells Clean Technology Systems Environmental division to Stellex affiliate for net proceeds €250M. KWS SAAT SE & Co. KGaA (KWS.GR) to sell its 50% stakes in two North American joint ventures. UBS (UBSG.SW) announces $2B share repurchase program. BayWa (BYW6.GR) preparing to sell its Australian renewables business, according to the Australian Financial Review. Banca CF+ to make offer for Banca Sistema ((BST.IM); terms unreported - Bloomberg

  • Macro/politics

    • UK business confidence levels hit highest since 2015, Lloyds says -- Reuters

    • UK-US trade deal kicks into gear: immediate tariff cuts for UK auto and aerospace sectors -- gov.uk

    • Global M&A powered by larger deals in first half; bankers show appetite for megadeals -- Reuters

  • Top company news

    • Earnings/updates

      • 1U1.GR (1&1 AG) -- guides FY adjusted EBITDA €545M vs prior guidance €571M and FactSet €575.0M [9 est, €543-641M]

      • SAN.FP (Sanofi) -- reports Q2 currency impacts between (3.5%) and (4.5%) on sales -- Aide Memoire (

      • Also reporting today

        • Earnings:

          • Benelux: BioSenic (BIOS.BB)

          • Southern Europe: MIG Holdings (MIG.GA)

          • UK: Polar Capital Holdings (POLR.LN), Porvair (PRV.LN), Ricardo (RCDO.LN)

        • Trading Update:

          • UK: TT Electronics (TTG.LN)

        • CMD/events: Symrise (SY1.GR), Mercedes-Benz (MBG.GR) pre-close call, Deutsche Börse (DB1.GR) ISS Stoxx investor day, Pharming Group (PHARM.NA), Tritax Big Box REIT (BBOX.LN)

    • M&A

      • VOW.GR (VW), RIVN (Rivian) -- Volkswagen increasing its stake Rivian; now transferring second tranche of $1B -- dpa

      • DUE.GR (Duerr) -- sells Clean Technology Systems Environmental division to Stellex affiliate for net proceeds €250M

      • KWS.GR (KWS SAAT SE & Co. KGaA) -- to sell its 50% stakes in two North American joint ventures

      • ROU.BB (Roularta Media Group) -- Koinon publishes a prospectus supplement in the context of its public takeover bid for Roularta Media Group

      • BP.LN (BP) -- UK government would allow Shell to buy BP - Mail on Sunday

      • TTE.FP (TotalEnergies) -- receives two bids for its Argentina shale oil assets - Bloomberg, citing people familiar with the matter

      • IBE.SM (Iberdrola) -- Scottish Power, Ovo Energy in early stages of exploring merger - Sky News

      • ADXN.SW (Addex Therapeutics) -- leads CHF2M investment in Stalicla

      • BYW6.GR (BayWa) -- preparing to sell its Australian renewables business - Australian Financial Review

      • ECR.SM (Ercros) -- Ercros' chairman comments on takeover offers from Bondalti and Esseco at shareholders meeting

      • BST.IM (Banca Sistema) -- Banca CF+ to make offer for Banca Sistema; terms unreported - Bloomberg

      • Though not in exclusive talks, KKR frontrunner to buy NewDay Group - Sky News

      • BLC.FP (Bastide Le Confort Medical) -- sells Baywater Healthcare To Sapio Group; price undisclosed

    • Healthcare

      • GSK.LN (GSK Plc) -- Senator Hassan launches investigation into GSK asthma inhaler maneuvers - STAT News

      • SAN.FP (Sanofi) -- Sanofi's Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy

      • SOBI.SS (Swedish Orphan Biovitrum) -- Swedish Orphan announces that FDA approved Gamifant sBLA for adults and children with HLH/MAS

      • HIK.LN (Hikma Pharmaceuticals) -- announces $1B investment by 2030 to further expand its US manufacturing and R&D capabilities

      • IDIA.SW (Idorsia) -- Idorsia's synthetic glycan vaccine platform validated for the first time in humans

    • Other

      • UBSG.SW (UBS) -- announces $2B share repurchase program

      • OCDO.LN (Ocado Group) -- risks losing £21.7M on the collapse of Jones Food -- The Telegraph

      • LR.FP (Legrand) -- agrees to amend and extend syndicated multi-currency loan

      • APAM.NA (Aperam) -- releases corporate sustainability report 2024

      • All Subjected Banks in Federal Reserve Stress Test Pass:

      • Estimated weekend box office revenues in US, Canada $125.7M, (18.5%) y/y - Box Office Mojo

      • Federal Reserve releases 2025 Dodd-Frank Act Stress Test (DFAST) for 22 banks

      • Follow-up: Federal Reserve releases 2025 Dodd-Frank Act Stress Test (DFAST) for 22 banks

  • Key rating changes

    • Upgrades

      • Deutsche Bank upgrades CTPNV.NA, GFC.FP

      • HOLN.SW (Holcim) -- to buy from hold at Jefferies

      • KARN.SW (Kardex Holding) -- to buy from hold at Kepler Cheuvreux

    • Downgrades

      • MONC.IM (Moncler) -- to neutral from buy at Goldman Sachs

      • CNA.LN (Centrica) -- to neutral from overweight at JPMorgan

      • TEL2.B.SS (Tele2) -- to sell from hold at Handelsbanken

      • EMG.LN (Man Group) -- to add from buy at Peel Hunt

      • LIFCO.B.SS (Lifco) -- to hold from buy at Handelsbanken

      • ARJO.B.SS (Arjo) -- to hold from buy at Nordea

      • NDX1.GR (Nordex) -- to hold from buy at Kepler Cheuvreux

    • Other Actions

      • ZAL.GR (Zalando) -- assumed buy at Jefferies

      • CRDA.LN (Croda International) -- initiated reduce at Kepler Cheuvreux

  • Data

    • Nikkei +0.86% to 40498.02

    • Hang Seng (0.29%) to 24214.73

    • Shanghai Composite +0.45% to 3439.51

    • S&P futures +26.5 vs prior close of 6223.8

    • €-$ +0.0002 or +0.02% to 1.1727

    • $-¥ (0.57) or (0.39%) to 143.89

    • €-¥ (0.62) or (0.37%) to 168.75

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE